ZyVersa Therapeutics

ZyVersa Therapeutics is a clinical-stage biopharma founded in 2021, headquartered in Weston, Florida. The company is advancing two distinct, in-licensed platforms: IC 100, a monoclonal antibody targeting the inflammasome adaptor protein ASC to broadly inhibit inflammation, and VAR 200, a cholesterol efflux mediator designed to treat renal diseases by removing pathogenic lipids from kidney cells. ZyVersa's strategy targets large market opportunities in inflammatory and renal diseases, initially focusing on cardiometabolic conditions and orphan renal disease FSGS, with plans for indication expansion and strategic partnerships.

Two proprietary platforms: 1) Inflammasome inhibition via a monoclonal antibody (IC 100) targeting the adaptor protein ASC to broadly inhibit multiple inflammasome types and block initiation/propagation of inflammation. 2) Renal lipotoxicity treatment via a cholesterol efflux mediator (VAR 200) to remove pathogenic lipids from kidney cells.

In inflammasome inhibition, ZyVersa's IC 100 differentiates by targeting ASC to inhibit multiple inflammasome types, competing against numerous companies developing specific NLRP3 inhibitors. In renal disease, VAR 200's focus on renal lipotoxicity is novel, competing against therapies targeting inflammation, fibrosis, and metabolic pathways in conditions like FSGS and DKD from larger biopharma players.